WaferGen Announces First Commercial Sale of ICELL8 Single-Cell System to Major Global Pharmaceutical Company

WaferGen Bio-systems, Inc.

today announced the first commercial sale of WaferGen's ICELL8™ Single-Cell System to a major global pharmaceutical company. The system will enable greater single-cell throughput, and provide key insights to be used in important cancer-related research initiatives. "The first commercial sale of our ICELL8 Single-Cell System is a significant milestone for WaferGen," said Rolland Carlson, President and Chief Executive Officer of WaferGen. "Based on the extensive results generated from our early access partners and in-house WaferGen research and development initiatives that have demonstrated the system's performance and utility, we think the ICELL8 has significant commercial potential. The ability to select specific cells based on cell imaging, combined with user friendly and cost-efficient processing methods, makes the ICELL8 very attractive to our targeted corporate and academic customers." The ICELL8 Single-Cell System is a revolutionary platform which can isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing. The system also includes an imaging station and CellSelect™ software for imaging each nanowell and automatic selection of single cells for downstream processing. Recently, WaferGen presented proof of concept results at the Single Cell Analyses Conference